Immunotherapy trial aims to shrink inoperable colon tumors
NCT ID NCT05131919
Summary
This study is testing whether the immunotherapy drug pembrolizumab can shrink tumors in people with a specific type of locally advanced colon cancer that cannot be surgically removed. It will involve 25 participants who will receive the drug intravenously every three weeks. The main goal is to see if the treatment leads to a measurable reduction in tumor size, which could potentially make surgery an option later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
Conditions
Explore the condition pages connected to this study.